Immunogenicity of cholera vaccination in children with inflammatory bowel disease

Dembiński, Łukasz; Stelmaszczyk-Emmel, Anna; Sznurkowska, Katarzyna; Szlagatys-Sidorkiewicz, Agnieszka; Radzikowski, Andrzej; Banaszkiewicz, Aleksandra

doi:10.1080/21645515.2021.1884475

“…Although one mouse died in the first in vivo experiment due to severe colitis associated with high body weight loss overall there was no significant difference in mortality rate amongst the groups. This supports the clinical data reported by Dembiński et al showing that, while less immunogenic than in healthy children, WC-rBS vaccine is safe and well tolerated in IBD patients [ 23 ]. It should be noted that there was a difference in global inflammation level among the animal studies performed, despite employing the same experimental protocol.…”

Section: Discussionsupporting

confidence: 90%

“…Repurposing the WC-rBS vaccine in IBD would have several advantages. WC-rBS safety has been demonstrated in IBD patients [ 23 ] as well as healthy subjects for more than 20 years. Further clinical development would require likely refinement including multiple administrations of WC-rBS vaccine, but time and cost could be saved by bypassing Phase 1 safety studies, especially if low WC-rBS vaccine doses are confirmed to be the most promising in the prevention and/or treatment of IBD.…”

Section: Discussionmentioning

confidence: 99%

An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease

Meunier,

Spillmann,

Rousseaux

et al. 2023

PLoS ONE

0

View full text Add to dashboard Cite

The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First in vitro endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients.

show abstract

An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease

Meunier¹,

Spillmann

²

,

Rousseaux

³

et al. 2023

Preprint

0

View full text Add to dashboard Cite

The oral cholera vaccine WC-rBS consists of 4 different inactivated strains of Vibrio cholerae (LPS source) admixed with recombinant cholera toxin B subunit. Because of its unique composition and anti-inflammatory properties reported for both CTB and low doses of LPS from other Gram-negative bacteria, we speculated that WC-rBS might have anti-inflammatory potential in a chronic autoimmune disease such as inflammatory bowel diseases. First in vitro endotoxin tolerance experiments showed the surprising WC-rBS potential in the modulation of inflammatory responses on both PBMCs and THP1 cells. WC-rBS was further evaluated in the Dextran Sodium Sulfate colitis mouse model. Administrated orally at different dosages, WC-rBS vaccine was safe and showed immunomodulatory properties when administered in a preventive mode (before and during the induction of DSS colitis) as well as in a curative mode (after colitis induction); with improvement of disease activity index (from 27 to 73%) and histological score (from 65 to 88%). Interestingly, the highest therapeutic effect of WC-rBS vaccine was observed with the lowest dosage, showing even better anti-inflammatory properties than mesalamine; an approved 5-aminosalicylic acid drug for treating IBD patients. In summary, this is the first time that a prophylactic medicine, safe and approved for prevention of an infectious disease, showed a benefit in an inflammatory bowel disease model, potentially offering a novel therapeutic modality for IBD patients.

show abstract

Vaccines in Children with Inflammatory Bowel Disease: Brief Review

Esposito

¹

,

Antoniol

²

,

Labate

³

et al. 2021

View full text Add to dashboard Cite

Incidence of inflammatory bowel diseases (IBDs), including Crohn’s disease (CD) and ulcerative colitis (UC), is increasing worldwide. Children with IBDs have a dysfunctional immune system and they are frequently treated with immunomodulating drugs and biological therapy, which significantly impair immune system functions and lead to an increased risk of infections. Vaccines are essential to prevent at least part of these infections and this explains why strict compliance to the immunization guidelines specifically prepared for IBD patients is strongly recommended. However, several factors might lead to insufficient immunization. In this paper, present knowledge on the use of vaccines in children with IBDs is discussed. Literature review showed that despite a lack of detailed quantification of the risk of infections in children with IBDs, these children might have infections more frequently than age-matched healthy subjects, and at least in some cases, these infections might be even more severe. Fortunately, most of these infections could be prevented when recommended schedules of immunization are carefully followed. Vaccines given to children with IBDs generally have adequate immunogenicity and safety. Attention must be paid to live attenuated vaccines that can be administered only to children without or with mild immune system function impairment. Vaccination of their caregivers is also recommended. Unfortunately, compliance to these recommendations is generally low and multidisciplinary educational programs to improve vaccination coverage must be planned, in order to protect children with IBD from vaccine-preventable diseases.

show abstract

Immunogenicity of cholera vaccination in children with inflammatory bowel disease

Cited by 3 publications

References 42 publications

An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease

An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease

An oral cholera vaccine in the prevention and/or treatment of inflammatory bowel disease

Vaccines in Children with Inflammatory Bowel Disease: Brief Review

Contact Info

Product

Resources

About